File(s) not publicly available
The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists
journal contribution
posted on 2023-06-08, 19:29 authored by David W Porter, Michelle Bradley, Zarin Brown, Riccardo Canova, Steven Charlton, Brian Cox, Peter Hunt, David Kolarik, Sarah Lewis, Des O'Connor, John Reilly, Carsten Spanka, Lauren Tedaldia, Simon J Watson, Roland Wermuth, Neil J PressA hit-to-lead optimisation programme was carried out on the Novartis archive screening hit, pyrazolopyrimidine 2-methyl-5-((phenylthio)methyl)pyrazolo[1,5-a]pyrimidin-7-ol 1, resulting in the discovery of CXCR2 receptor antagonist 2-benzyl-5-(((2,3-difluorophenyl)thio)methyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 14. The SAR was investigated by systematic variation of the pendant thiol, alkyl and pyrimidinol groups. Replacement of the pyrazolopyrimidine core with a triazolo alternative led to a dual series of antagonists with favourable biological and pharmacokinetic properties.
History
Publication status
- Published
Journal
Bioorganic and Medicinal Chemistry LettersISSN
0960-894XPublisher
ElsevierExternal DOI
Issue
1Volume
24Page range
72-76Department affiliated with
- Chemistry Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2015-01-12Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC